Advanced targeted therapies for invasive cancers

Invasight is a Swiss-based early-clinical stage biotech start-up. Our breakthrough technology, ACINDA accelerates drug discovery and enables design of specific protein-protein interaction inhibitors (PPIs) for non-traditional intercellular protein targets, which cause cancer cell invasion. Our first-in-class PPIs combine potent anti-tumour activity with a favourable safety profile for patients with invasive cancers. The most advanced of these first-in-class, protein-protein interaction inhibitors is F2i, a inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development.

Get in touch

Leave a message and we'll be in contact.

Find us